Mirum Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mirum Pharmaceuticals (MIRM).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

4S.Buy

12Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$117Upside to Avg. PT+36.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$135→$155
Sep 29, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$145→$160
Sep 29, 2026	Baird	Brian Skorney	PT Raise	Outperform	$123→$130
Sep 28, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$140→$195
Aug 27, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$137
Aug 6, 2026	TD Cowen	Joseph Thome	PT Cut	Buy	$145→$140
Aug 6, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$148→$135
Aug 6, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$146→$137
Aug 6, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$185→$140
Jul 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$142→$148
Jul 2, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$115→$125
Jun 15, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$140→$146
Jun 11, 2026	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$140→$150
Jun 2, 2026	Citigroup	Yigal Nochomovitz	Initiate	Buy	$145
May 19, 2026	Wolfe Research	Kalpit Patel	Initiate	Outperform	$145
May 7, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$125→$145
May 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$128→$142
May 7, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$135→$138
May 7, 2026	Baird	Brian Skorney	PT Raise	Outperform	$112→$129
May 5, 2026	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$130→$140

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $123 to $130.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $195.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target

Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.

Benzinga Newsdesk

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155

PRO
Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

PRO
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130

PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195

PRO
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target

PRO
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

People Also Watch

People Also Watch

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155

PROCitigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

PROBaird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130

PROHC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195

PROCitizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target

PROTD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155

PRO
Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

PRO
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130

PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195

PRO
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target

PRO
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140